...
Authors
Clear selection
...
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia

Clin Res Cardiol. 2022 Feb 27.
doi:10.1007/s00392-022-01993-5

Conflicts of interests: Profs. Mahfoud and Böhm are supported by Deutsche Forschungsgemeinschaft (SFB TRR219). Prof. Mahfoud is supported by Deutsche Gesellschaft für Kardiologie and has received scientific support and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, and ReCor Medical. Prof. Böhm has received consulting fees from Abbott Vascular, Bayer AG, Amgen, AstraZeneca, Servier, Medtronic, Vifor, and Boehringer Ingelheim. Prof. Kintscher received research grants from Bayer AG, and speaker honoraria from Amarin, Bayer AG, Berlin Chemie, Novartis, Servier, and Sanofi, and participated in advisory boards of Berlin Chemie, Boehringer Ingelheim, Novartis, and Sanofi. All the other authors have reported that they have no relationships relevant to the contents of this paper to disclose.